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Expression of multidrug pumps including P-glycoprotein (MDR1, ABCB1) in the plasma membrane of tumor cells often results
in decreased intracellular accumulation of anticancer drugs causing serious impediment to successful chemotherapy. It has
been shown earlier that combined treatment with UIC2 anti-Pgp monoclonal antibody (mAb) and cyclosporine A (CSA) is
an effective way of blocking Pgp function. In the present work we investigated the suitability of four PET tumor diagnostic
radiotracers including 2-[18F]fluoro-2-deoxy-D-glucose (18FDG), 11C-methionine, 3󸀠-deoxy-3󸀠-[18F]fluorothymidine (18F-FLT),
and [18F]fluoroazomycin-arabinofuranoside (18FAZA) for in vivo follow-up of the efficacy of chemotherapy in both Pgp positive
(Pgp+) and negative (Pgp−) human tumor xenograft pairs raised in CB-17 SCID mice. Pgp+ and Pgp− A2780AD/A2780 human
ovarian carcinoma and KB-V1/KB-3-1 human epidermoid adenocarcinoma tumor xenografts were used to study the effect of the
treatment with an anticancer drug doxorubicin combined with UIC2 and CSA. The combined treatment resulted in a significant
decrease of both the tumor size and the accumulation of the tumor diagnostic tracers in the Pgp+ tumors. Our results demonstrate
that 18FDG, 18F-FLT, 18FAZA, and 11C-methionine are suitable PET tracers for the diagnosis and in vivo follow-up of the efficacy
of tumor chemotherapy in both Pgp+ and Pgp− human tumor xenografts by miniPET.
1. Introduction
The miniPET technique is a well-established noninvasive
method to detect tumors and follow up the effect of therapy
of tumors, using PET tumor diagnostic tracers. The PET
tumor diagnostic tracers, like 11C-metionine, 2-[18F]fluoro-
2-deoxy-D-glucose (18FDG), and (3󸀠-deoxy-3󸀠-[18F]fluoro-
thymidine) (18F-FLT), are good candidates to measure the
effect of the therapy. 18FDG, an analog of glucose, the most
commonly used PET radiotracer in clinical oncology, allows
visualization of the changes in the glucose metabolic rate in
tumors [1–3]. 18FDG undergoes phosphorylation by hexok-
inase but can not pass through the rest of glycolysis, and it
remains trapped in the cell. Increased cell proliferation is
one of the main features of cancer cells. 18F-FLT is used as a
PET tracer for visualization of cell proliferation.The trapping
of 18F-FLT was demonstrated with the uptake of thym-
idine analogue after phosphorylation by thymidine kinase 1
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(TK1) in the S phase of cell cycle [4, 5]. Another tumor dia-
gnostic PET tracer is the 11C labelled methionine applied for
the follow-up of the amino acid transport and metabolism in
the tumor [6]. Radiolabeled nitroimidazole derivatives (e.g.,
[18F]fluoroazomycinarabinofuranoside (18F-FAZA) and [18F]-
fluoromisonidazole (18F-MISO)) validated markers to detect
hypoxia in cancer cells. Nitroimidazoles labeled with 18F iso-
tope can undergo an oxygen-reversible single-electron reduc-
tion under hypoxic conditions, forming reactive oxygen radi-
cals that subsequently bind covalently tomacromolecular cel-
lular components and are trapped in the intracellular space;
consequently they are suitable tracers for in vivo detection
of hypoxia in tumors. Hypoxia in tumor seems to be an
important prognostic factor of chemotherapy response [7].
Multidrug resistance (MDR) seems to be the most widely
observed mechanism in clinical cases of chemotherapy
resistance. This phenomenon is often associated with the
overexpression of certain ATP binding cassette transporters
including P-glycoprotein (Pgp, coded by the MDR1 gene),
which is an ATP dependent active efflux pump that is able to
extrude a large variety of chemotherapeutic drugs from the
cells [8, 9].
The conformation sensitive UIC2 mouse monoclonal
antibody inhibits Pgpmediated substrate transport.However,
this inhibition is usually partial and its extent is variable, since
UIC2 binds only to 10–40%of all Pgpmolecules present in the
cell membrane [10, 11]. It has been shown earlier in in vitro
and ex vivo experiments that the combined administration
of UIC2 antibody and certain substrates or modulators
used at low concentrations increases the antibody binding,
leading to a near complete Pgp inhibition, thus providing a
novel, specific, and effective way of blocking Pgp function
[11, 12]. Krasznai et al. [12] also demonstrated that the com-
bined treatment with UIC2 antibody and Pgp modulators
effectively blocked the function of Pgp in ovarian carcinoma
cells in vitro and the effect could be followed by using tumor
diagnostic tracers, 99mTc-MIBI and 18FDG.
Ovarian cancer is the secondmost common cancer of the
female genital tract but accounts for over half of all deaths
related to gynecologic neoplasms [13]. Anthracycline antibi-
otics have been used for more than 40 years in the treatment
of gynecologic tumors in the first line in monotherapy or in
combination with other drugs [14, 15].
In this paper using an animal model we demonstrate
that theminiPET technique combined with tumor diagnostic
radiopharmaceuticals is suitable for the detection of either
Pgp expressing or Pgp nonexpressing tumors and it can be
applied for in vivomonitoring of the effect of tumor therapy.
2. Materials and Methods
2.1. Cell Lines. Drug sensitive (Pgp+) cell lines and their non-
sensitive (Pgp−) counterparts were used in the experiments.
Human epidermoid (cervix) carcinoma cell lines—KB-V-
1 (Pgp+), KB-3-1 (Pgp−)—and human ovarian carcinoma
cell lines—A2780AD (Pgp+), A2780 (Pgp−)—were grown as
monolayer cultures at 37∘C in a 95% humidified air, 5% CO
2
atmosphere. The cell lines were maintained in 75 cm2 flasks
in Dulbecco’s modified Eagle’s medium (DMEM) containing
4.5 g/L glucose and supplemented with 10% heat-inactivated
fetal bovine serum (FBS), 2mM L-glutamine, and 25 𝜇M/mL
gentamicin.The KB-V-1 cells were cultured in the presence of
180 nMvinblastine and theA2780ADcells were culturedwith
2 𝜇M doxorubicin until use. The viability of the cells used in
our experiments was always higher than 90%, as assessed by
the trypan blue exclusion test.
2.2. Laboratory Animals. Twenty-four (10- to 12-week-old)
pathogen-free B-17 severe combined immunodeficiency
(SCID) female mice were used in this study. Animals were
housed under pathogen-free conditions in air conditioned
rooms at a temperature of 26 ± 2∘C, with 50 ± 10% humidity
and artificial lighting with a circadian cycle of 12 h. The diet
and drinking water (sterilized by autoclaving) were available
ad libitum to all the animals. The Principles of Laboratory
Animal Care (National Institute of Health) were strictly
followed, and the experimental protocol was approved by the
Laboratory Animal Care and Use Committee of the Univer-
sity of Debrecen.
2.3. Animal Model and Study Design. SCID mice were
injected subcutaneously (s.c.) with KB-3-1 (1.5 × 106 cells in
150 𝜇L PBS) cells on the left andKB-V-1 (3× 106 cells in 150 𝜇L
PBS) cells on the right side. Other groups of SCID mice were
injected s.c. with A2780 (3 × 106 cells in 150 𝜇L PBS) cells on
the left and A2780AD (4.5 × 106 cells in 150 𝜇L PBS) cells on
the right side. On each side the animals received two injec-
tions of the same cell line, one in the shoulder and one in the
thigh to double the tumor numbers per animal in order to
limit the number of animals and to maximize the number of
tumors imaged. Preliminary experiments showed that, in
contrast to the Pgp− cells, the tumor formation from Pgp+
cells has a slower kinetics.This differencewas equalized by the
injection of different cell numbers. Four days after the injec-
tion mice were treated with doxorubicin (DOX) (5mg/kg)
combined with UIC2 monoclonal antibody (5mg/kg) and
cyclosporine A (CSA) (10mg/kg). Tumor growth was asse-
ssed by caliper measurements every two days by the same
experienced researcher. The tumor size was calculated
using the following formula: (largest diameter × smallest
diameter2)/2 [16].
2.4. Radiotracers. The glucose analog (18FDG) was synthe-
sized and labeled with the positron-decaying isotope 18F
according to Hamacher et al. [17]. The radiosynthesis of the
thymidine analog (18F-FLT) was performed according to the
published method by Grierson and Shields [18]. 11C-
Methionine was synthesized as described by Mitterhauser
et al. [19].The 18F-labeled nitroimidazole compound fluoroa-
zomycin arabinoside (18FAZA) was performed according to
the published method by Piert et al. [7].
2.5. Small Animal PET Imaging Using Radiopharmaceuticals.
After the implantation 18FDG, 11C-methionine, and 18F-FLT
scans were repeated at different time points. Prior to PET,
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mice were fasted overnight. On the day of PET imaging mice
were prewarmed to a body temperature of 37∘C and this tem-
peraturewasmaintained throughout the uptake and scanning
period to minimize the brown fat visualization. Mice were
injected via the tail vein with 5.0 ± 0.2MBq of 18FDG, 8.1 ±
0.6MBq of 11C-methionine, 4.5±0.2MBq of 18F-FLT, or 5.5±
0.5MBq of 18FAZA. 20min after 11C-methionine or 40min
after 18FDG or 18F-FLT or 120min after 18FAZA tracer injec-
tion animals were anaesthetized by 3% isoflurane with a ded-
icated small animal anesthesia device. 20min static single-
frame PET scans were acquired using a small animal PET
scanner (miniPET-II, Department of Nuclear Medicine,
Debrecen) to visualize the tumors. On the same animal the
11C-methionine and 18FDG and 18F-FLT scans were made
within 4 days.
The miniPET-II scanner consists of 12 detector modules
including LYSO scintillator crystal blocks and position sen-
sitive PMTs [20]. Each crystal block comprises 35 × 35 pins
of 1.27 × 1.27 × 12mm size. Detector signals are processed by
FPGA based digital signal processing boards with embedded
Linux operating system. Data collection and image recon-
struction are performed using a data acquisitionmodule with
Ethernet communication facility and a computer cluster of
commercial PCs. Scanner normalization and random correc-
tion were applied on the data and the images were recon-
structed with the standard EM iterative algorithm. The voxel
size was 0.5 × 0.5 × 0.5mm and the spatial resolution varies
between 1.4 and 2.1mm from central to 25mm radial dis-
tances [20]. The system sensitivity is 11.4%.
2.6. PET Data Analysis. Radiotracer uptake was expressed
in terms of standardized uptake values (SUVs) and tumor
to muscle (T/M) ratios. Ellipsoidal 3-dimensional volume of
interest (VOI) was manually drawn around the edge of the
tumor xenografts activity by visual inspection using Brain-
Cad software (http:/www.minipetct.hu/). The standardized
uptake value (SUV) was calculated as follows: SUV = [VOI
activity (Bq/mL)]/[injected activity (Bq)/animal weight (g)],
assuming a density of 1 g/cm3.The T/M ratios were computed
as the ratio between the mean activity in the tumor VOI and
in the background (muscle) VOI.
2.7. Whole-Body Autoradiography. For whole-body autora-
diography the implantation of tumor cells was carried out as
described above. On the 16th day after epidermoid carcinoma
and on the 25th day after ovarian carcinoma cell implantation
tumor-bearing mice were anaesthetized and the radioligands
18F-FLT (4.5 ± 0.2MBq in 150𝜇L saline) or 18FDG (5.5 ±
0.2MBq in 150𝜇L saline) or 18FAZA (5.5±0.5MBq in 150 𝜇L
saline) were injected via the tail vein. Animals were euth-
anized 60min after the administration of 18FDG or 18FLT
and 120min after 18FAZA injection with 300mg/kg pen-
tobarbital (Nembutal). Each animal was embedded in 1%
carboxymethylcellulose solution. After being frozen in liquid
nitrogen, 60𝜇m thin cryostat sections (Leica CM 3600
cryomacrotome, Nussloch, Germany) were cut in the coronal
plane. Sections were exposed to phosphorimaging plates (GE
Healthcare, Piscataway, NJ, USA). For anatomic correspon-
dence true color images of the sections were also obtained
by a transparency scanner (Epson Perfection 1640, EPSON
Deutschland GmbH, Meerbusch, Germany). Autoradiogra-
phy and transmission images were overlaid to fuse the func-
tional and anatomical information. For phosphorimage anal-
ysis of selected sections the ImageQuant 5.0 (GE Healthcare,
Piscataway, NJ, USA) image analyzing software was used.
2.8. Tumor Sample Preparation. 16 days after epidermoid car-
cinoma and 25 days after ovarian carcinoma cell implantation
mice were euthanized with an overdose of pentobarbital and
tumorswere dissected from the animals. Tumor samples were
embedded in cryomatrix and snap-frozen in liquid nitrogen.
Samples were stored at −80∘C in an ultralow temperature
freezer.
2.9. Immunohistochemistry. Immunohistochemistrywas per-
formed on 5 𝜇m thick frozen tumor sections. Frozen sections
were dried at room temperature and fixed in precooled
acetone (−20∘C) for 10min. Sections were then washed and




in methanol for 20min to quench
endogenous peroxidase activity. After blocking the nonspe-
cific binding with 1% BSA for 20minutes, sections were incu-
bated for 60min at room temperature with mouse anti-Pgp
monoclonal antibody UIC2 (10 𝜇g/mL). After two washes
with PBS, anti-mouse EnVision Detection Systems DAB
(Dako, Denmark) was used to visualize the primary anti-
bodies and sections were counterstained with haematoxylin.
Negative controls were obtained by omitting the primary
antibody.
2.10. Flow Cytometric Measurements. Formaldehyde (1% in
PBS) prefixed cells were centrifuged at 500×g for 5min and
washed twice with 1% PBS/BSA. To visualize the Pgp expres-
sion, cells (1 × 106 cells/mL) were incubated with 10𝜇g/mL of
UIC2 mAb in PBS containing 1% BSA (PBS/BSA) at 37∘C for
40min. After two washes with ice-cold PBS, the cells were
incubated with rabbit anti-mouse Alexa 488 secondary
antibody (10 𝜇g/mL A488-GaMIgG, Invitrogen, CA) at 4∘C
for 30min. Negative controls were obtained by omitting
the primary antibody. A Becton-Dickinson FACScan flow
cytometer (Becton-Dickinson,MountainView, CA)was used
to determine fluorescence intensities. Emission was detected
through a 540 nmbroadband interference filter forAlexa 488.
Cytofluorimetric data were analyzed by BDIS CELLQUEST
(Becton-Dickinson) or FloWin (written by Drs. M. Emri and
L. Balkay, Department of Nuclear Medicine, University of
Debrecen) software.
2.11. Data Analysis. Data are presented as mean ± SEM of at
least three independent experiments. The significance was
calculated by Student’s 𝑡-test (two-tailed). The level of signif-
icance was set at 𝑃 ≤ 0.05 unless otherwise indicated.
3. Results
3.1. Flow Cytometric Studies. Flow cytometric analyses
showed a remarkably high expression of Pgp in the Pgp+ cells.






A2780 Pgp− A2780AD Pgp+ KB-3-1 Pgp− KB-V-1 Pgp+
Figure 1: Histopathological analysis of tumor xenografts. Autopsy images show the human ovarian (a) and human epidermoid carcinoma
(f) tumor xenografts 25 and 16 days after tumor cell implantation, respectively. Microscopic images of H&E staining ((b) A2780 Pgp−, (c)
A2780AD Pgp+; (g) KB-3-1 Pgp−, (h) KB-V-1 Pgp+) and UIC2 mAb-DAB immunostaining ((d) A2780 Pgp−, (e) A2780AD Pgp+; (i) KB-3-1
Pgp−, (j) KB-V-1 Pgp+) of xenograft tumor sections. Bar: 50𝜇m; magnification ×200.
The ratio of the relative mean fluorescence intensities of the
Pgp+/Pgp− ovarian carcinoma (A2780AD/A2780) and the
epidermoid adenocarcinoma (KB-V-1/KB-3-1) cell line pairs
was 12.7 ± 2.3 and 10.0 ± 1.8, respectively.
3.2. Histopathological Studies. SCID mice were injected in
their left and right sides with Pgp− (A2780, KB-3-1) and Pgp+
(A2780AD, KB-V-1) cells, respectively. No morphological
differences were seen between the congruous Pgp− and Pgp+
tumors upon histopathological analysis of harvested tumors
by haematoxylin-eosin (H&E) staining (Figures 1(b), 1(c),
1(g), and 1(h)). Tumor cells implanted into the SCID
mice retained their Pgp+ or Pgp− phenotype as proved by
immunostaining of Pgp. Immunoperoxidase detection
showed strong positive staining in Pgp+ tumor cell mem-
branes (Figures 1(e) and 1(j)); in contrast, no staining was
visible in Pgp− tumors (Figures 1(d) and 1(i)).
3.3. Impact of Combined Treatment on Tumor Volume. Four
days after the s.c. injection of tumor cells mice were treated
with a combination of UIC2monoclonal antibody, DOX, and
CSA. Other groups of animals (tumor-bearing control
(untreated)) were injected with PBS. The growth rate of the
ovarian carcinoma tumors (A2780 Pgp− andA2780ADPgp+)
was slower (doubling time: 4 days) than that of the epi-
dermoid carcinoma tumors (KB-3-1 Pgp− and KB-V-1 Pgp+;
doubling time: 3 days).The growth rates of the treated tumors
were compared to that of the untreated tumors in both the
cases of the Pgp+ and the Pgp− ones. In contrast to the control
(untreated) tumors, where exponential growth was observed,
the combined treatment inhibited the tumor growth
(Figure 2). In case of the human ovarian carcinoma
xenografts, from day 10 significant differences (on day 10: 𝑃 ≤
0.05, on day 25: 𝑃 ≤ 0.01) were observed between the treated
and untreated A2780AD and A2780 tumor volumes. These
results were similar to the experiments with the human
epidermoid carcinoma xenografts, where we found signifi-
cant differences in the volume (from day 8: 𝑃 ≤ 0.05,
from day 14: 𝑃 ≤ 0.01) of the control and treated tumors
(Figure 2(b)).
3.4. miniPET Imaging of Combined Treated and Untreated
Tumor Xenografts. For in vivo visualization of the effect
of the combined treatment on tumors 18FDG and 18F-FLT
miniPET scans were performed at different time points and
SUVmean, SUVmax, T/Mmean, and T/Mmax ratios were
calculated (Figure 3). Fifteen to twenty days after A2780 Pgp−
andA2780ADPgp+ cell implantation control (untreated) and
combined treated tumor-bearing mice (6 mice, 24 tumors)
received 18FDG and 18F-FLT. Control tumors demonstrated
high 18FDG and 18F-FLT uptake (Figure 3(a), left). Quantita-
tive image analysis showed significant differences (𝑃 < 0.001)
between the 18FDG avidity of treated Pgp+ (SUVmean =
0.33 ± 0.03 and SUVmax = 0.54 ± 0.06) and untreated Pgp+
(SUVmean = 1.62 ± 0.25 and SUVmax = 2.96 ± 0.6) tumors
and also between the treated Pgp− (SUVmean = 0.56 ± 0.03
and SUVmax = 0.94 ± 0.07) and untreated Pgp− (SUVmean
= 1.43 ± 0.17 and SUVmax = 2.51 ± 0.3) tumors. By taking
the T/M ratios, the differences between the treated and
untreated tumors were also significant (𝑃 < 0.001). The
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(b)
Figure 2: Impact of combined treatment on tumor growth. Pgp+ and Pgp− treated tumors’ volumes were compared to Pgp+ and Pgp− control
(untreated) tumors in tumor-bearing animals. Treatments began 4 days after tumor cell inoculations. (a) Impact of combined treatment on
A2780AD Pgp+ and A2780 Pgp− (6 mice, 24 tumors). (b) Impact of combined treatment on KB-V-1 Pgp+ and KB-3-1 Pgp− tumors (6 mice,
24 tumors). Statistically significant changes in tumor volume compared to the tumor volume of untreated control are indicated (∗𝑃 ≤ 0.05,
∗∗
𝑃 ≤ 0.01).
uptake of 18F-FLT was significantly increased at the control
tumors compared with that at the combined treated tumors
(Figure 3(b), left). The 18F-FLT miniPET imaging and SUV
values showed the efficiency of the combined treatment.
The biodistribution of 18FDG and 18F-FLT on days 10–15
following tumor inoculation in epidermoid carcinoma bear-
ing mice is shown in Figure 3(a). The results of 18FDG and
18F-FLT miniPET scans showed significant accumulation in
the untreated control tumors (Figure 3(a), right), in contrast
to the combined treated KB-V-1 Pgp+ and KB-3-1 Pgp−
tumors.
Overall, in the treated animals the T/M ratios showed
no difference in the 18FDG and 18F-FLT uptake between the
place of inoculation and its muscle environment, proving the
lack of tumor cells. No significant differences were observed
with these two radiopharmaceuticals in the SUV values
between Pgp+ and Pgp− tumors.
Fifteen to twenty days after A2780 Pgp− and A2780AD
Pgp+ cell implantation control (untreated) and treated
tumor-bearing mice received 11C-methionine. Control tum-
ors showed high 11C-methionine uptake (Figure 4(a)). Quan-
titative image analysis demonstrated that there were notable
differences between the 11C-methionine avidity of the treated
Pgp+ (SUVmean = 0.43±0.02 and SUVmax = 0.83±0.03) and
untreated Pgp+ (SUVmean= 1.35±0.46 and SUVmax= 2.20±
0.6) tumors and also between the treated Pgp− (SUVmean =
0.45 ± 0.03 and SUVmax = 0.84 ± 0.06) and untreated Pgp−
(SUVmean = 1.35 ± 0.8 and SUVmax = 2.40 ± 1.5) tumors.
The 11C-methionine miniPET imaging (Figure 4(b)) and
SUV values also showed the efficiency of the combined
treatment in case of the epidermoid tumor xenografts. 10–15
days after KB-3-1 and KB-V-1 tumor cell implantation the
quantitative image analysis showed notable differences
between the 11C-methionine uptake of the treated Pgp+
(SUVmean = 0.49 ± 0.03 and SUVmax = 0.84 ± 0.02) and
untreated Pgp+ (SUVmean= 1.52± 0.43 and SUVmax= 2.43±
0.68) tumors and also between the treated Pgp− (SUVmean =
0.49 ± 0.03 and SUVmax = 0.76 ± 0.05) and untreated Pgp−
(SUVmean = 1.48 ± 0.46 and SUVmax = 2.55 ± 1.0) tumors.
3.5. Assessment of Heterogeneity in Tumor Metabolism Using
Radiopharmaceuticals. The metabolic heterogeneity of con-
trol tumors was investigated on the same animal by 18FDG
(22 days after tumor cell injection), 18FAZA (23 days after
tumor cell injection), and 18F-FLT (24 days after tumor cell
injection) usingminiPET scanner and autoradiography tech-
niques. Control tumors demonstrated heterogeneous 18F-
FLT uptake, with some areas of moderate uptake surrounded
by areas of intense uptake, indicating the proliferation of
tumor cells. We found that the 18FDG positive tumor areas
and the 18F-FLT negative areas overlapped one another. The
18FAZA uptake of these areas was high. After the quantita-
tive analysis of the miniPET images the differences in the
metabolic activity of the investigated tumors are shown on a
representative figure (Figure 5). By taking the SUVmean
values we found the following: 18FDG avid areas: 1.20 ± 0.27,
not 18FDG avid areas: 0.79 ± 0.13; 18F-FLT avid areas: 2.67 ±
0.35, not 18F-FLT avid areas: 2.15 ± 0.19; 18FAZA avid-
hypoxic-areas: 0.70 ± 0.08, not 18FAZA avid-not hypoxic-
areas: 0.53 ± 0.07.
4. Discussion
Xenograft model and the miniPET technique are recently
commonly usednoninvasivemethods in preclinical studies to
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Figure 3: Effect of combined treatment on the 18FDG and 18F-FLT uptake of Pgp positive and negative human ovarian (left side) and
epidermoid carcinoma (right side) tumors. (a) 18FDG and 18F-FLT miniPET images of control and combined treated Pgp− (left side, black
arrows) and Pgp+(right side, red arrows) tumor-bearing mice (coronal sections). No tumors can be visualized in the treated animals. (b)
The SUVmean and SUVmax and the mean and maximum T/M ratios are displayed (bars represent mean ± SEM). Statistically significant
differences in comparison to combined treated tumors are indicated (∗𝑃 ≤ 0.05, ∗∗𝑃 ≤ 0.01, and ∗∗∗𝑃 ≤ 0.001).

























Figure 4: Effect of combined treatment on the 11C-methionine uptake of Pgp positive and negative human ovarian (a) and epidermoid
carcinoma (b) tumors. 11C-Methionine miniPET images of control and treated Pgp− (left side, black arrows) and Pgp+(right side, red arrows)
tumor-bearing mice (coronal sections). No tumors can be visualized in the treated animals.







Figure 5:miniPET andwhole-body autoradiography images from the same control tumor-bearing (ovarian carcinoma) SCIDmouse (upper).
Lower panels demonstrate the tumor heterogeneity using different radiopharmaceuticals on a representative Pgp+ tumor.White arrows: Pgp−
tumors; red arrows: Pgp+ tumors. Color bars regard to the PET images only.
detect and follow up the effect of therapy of human
tumors, using PET tumor diagnostic radiopharmaceuticals,
like 18FDG, 18F-FLT, 18FAZA, and 11C-methionine.
It has been demonstrated earlier by Goda et al. [11], and
Krasznai et al. [12] in their in vitro and ex vivo experiments
that the combined application of the Pgp specific antibody
UIC2 and cyclosporine A is a successful strategy to overcome
Pgp-mediated multidrug resistance.
In our experiments we used similar treatment carried
out on mouse xenografts. Our aim was to test the efficacy
of the combined treatment on drug sensitive and resistant
human ovary and cervix cancer xenograft models by using
in vivo medical imaging technique (miniPET) and the most
commonly applied tumor diagnostic radiopharmacons
(18FDG, 18F-FLT, and 11C-metionine) in the visualization of
gynecological tumors.
The tumor cells were inoculated at four places in each ani-
mal in order to provide self-control experiment and reduce
the necessary number of experimental animals.The presence
of Pgp in the tumors was proved by immunohistochemistry
(Figure 1).
The A2780 and A2780AD human ovarian tumors grew
slower than the epidermoid adenocarcinoma tumors (KB-3-1,
KB-V-1) (Figure 2). The treatment of the tumors started four
days after the inoculation using a dose of 5mg/kg doxoru-
bicin.The size of the tumors was small (2–5mm3) but visually
observable. Lee et al. [21] performed efficacy studies using
BALB/c mice bearing C-26 colon carcinoma tumors. In their
study they applied dendrimer-DOX in which the DOX was
attached bymeans of a stable carbamate bond in an equivalent
of 20mg/kg doxorubicin in a single dose 8 days after tumor
implantation, which caused complete tumor regression and
100% survival. Kratz et al. [22] published similar results: they
observed in both male and female mice an LD50 of doxoru-
bicin 12mg/kg. Graf et al. [23] have shown that tumor growth
was inhibited by a single dose of doxorubicin ranging from
25 𝜇g to 200𝜇g in xenograft lymphoma tumors. Kim et al.
[24] treated the human ovarian A2780/DOX carcinoma
8 BioMed Research International
xenografts with 10mg/kg DOX three times at 3-day intervals
without any effect of the MDR resistant tumor growth.
In our work we diagnosed the presence and followed the
growth of multidrug sensitive and resistant tumors as well
as the efficacy of the combined treatment with three tumor
diagnostic tracers.The results show that the 18FDG (a glucose
metabolic tracer), 11C-methionine (tracer for amino acid
transport and protein synthesis), and the 18F-FLT (a prolif-
eration tracer) can be effectively used for monitoring both
the Pgp+ and the Pgp− tumors. The accumulation of the
tracers could be followed by definite SUV values although the
18F-FLT SUV values were higher than that of the 18FDG
(Figure 3) Ong et al. [25] called attention to the fact that the
PET tracer accumulation can be different in in vitro exper-
iments with tumor cells and in xenografts made from the
same cells in vivo; therefore the pharmacon uptake should be
tested. Xenografts in vivo can be less sensitive to PET tumor
diagnostic tracers than cell lines in vitro. In our experiments
in both theA2780 and theA2780AD, aswell as theKB-3-1 and
KB-V-1 Pgp+ and Pgp− cell line pairs, just as the xenografts
made with these cell lines, all three tumor diagnostic tracers
(18FDG, 18F-FLT, and 11C-methionine) could be well used.
Jensen et al. [5] used ovarian cancer (A2780) xenografts
in nude mice and they—similarly to our results—measured
higher 18F-FLT than 18FDG uptake. On the other hand they
measured approximately 50% lower SUVmean and SUVmax
values compared to our results. The differences can be
explained by the different experimental protocols and the bio-
logical differences between the nude and SCID mice. Eben-
han et al. [26] used KB-3-1 cervix carcinoma xenograftmodel
(in nude mice) and found that the xenografts showed low
18FDG SUV and were better visualized by 18F-FLT. It is in
agreement with other studies reporting that for assessing the
early response to anticancer treatment 18F-FLT was supe-
rior to 18FDG [5]. However, other studies found higher
18FDG uptake compared to 18F-FLT accumulation in several
xenograft models [27, 28]. In our experiments both tracers
showed good visualization of the Pgp+ and Pgp− tumors and
the efficacy of the treatment.
18FDG, the most commonly used PET radiotracer in
tumor diagnostics, allows visualization of the changes in the
glucose metabolic rate in tumors [3]. Since Pgp is a transport
ATPase, its activity may increase the ATP demand of the cells
expressing it at high level [12]. The increased energy demand
of the cancer cells manifests in higher glucose metabolisms
that can be measured by 18FDG accumulation, but a number
of factors can affect the FDG uptake in tumors [1, 3, 29, 30].
The different proliferation activity of the different tumors
as well as the variance in the tumor volume suffering
hypoxiamay result in further differences in the 18FDGuptake
(Figure 5). Similarly to our results, several authors report het-
erogeneity in the 18FDG uptake of different tumors [31, 32].
The experimental model used in our experiments provides
exactly the same extracellular conditions (free glucose con-
centration in the blood, injected radiotracer dose, anaes-
thetizing procedure, etc.) since both of the Pgp+ and the Pgp−
tumors grow in the same mice; therefore the measured
differences in the accumulation of the radiopharmacon show
the intrinsic characters of the tumors.
In our experiments, we initiated the treatment of the
tumors four days after the inoculation of the cells, when the
gynecologic tumors were still rather small. We aimed to dev-
elop a model analogous to the clinical situation, when after
removing the tumor by surgery a systemic therapy is applied
to hinder the development of multidrug resistant primary or
metastatic tumors.
Our results show that the above described combined
treatment is an effectivemethod for the chemotherapy of both
Pgp+ and Pgp− human ovarian carcinoma and epidermoid
adenocarcinoma tumors growing in mice, and the efficacy of
the treatment can be followed by miniPET using 18FDG, 18F-
FLT, and 11C-methionine radiotracers. In addition, 18FAZA is
a suitable tracer to detect the hypoxia of the tumor in xeno-
grafts. Using multitracer miniPET 18FDG, 18F-FLT, and
18FAZA analyses also help to detect the metabolic hetero-
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